Marijuana has long been demonized as a trigger for psychosis, and for some people, it may well be dangerous.
Now, new research is shining a light on what a handful of pioneering scientists first suggested 40 years ago; that cannabinoids may be good medicine for people suffering schizophrenia.
CBD has “beneficial effects in patients with schizophrenia,” says a study published in the medical journal of the American Psychiatric Association.
The medical researchers concluded that “CBD may represent a new class of treatment for the disorder.”
Funded by pharmaceutical giant GW Pharmaceuticals, this robust scientific study, had patients with schizophrenia receive CBD alongside their existing antipsychotic medication.
After six weeks of treatment, compared with the placebo group, the CBD group had “lower levels of positive psychotic symptoms and were more likely to have been rated as improved and as not severely unwell by the treating clinician.”
The CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups.
The research findings were presented in the March 2018 issue of the American Journal of Psychiatry.